Quarterly Portfolio Disclosure

As of June 30, 2024

Summary of Investment Portfolio

PORTFOLIO ALLOCATION	% OF NAV
Equities	95.1
Cash and cash equivalents	5.3
Other assets (liabilities)	(0.4)

REGIONAL ALLOCATION	% OF NAV
United Kingdom	21.8
France	16.4
Netherlands	13.8
Switzerland	12.7
Denmark	8.2
Cash and cash equivalents	5.3
Ireland	4.1
Italy	3.8
Spain	3.8
Germany	3.6
Sweden	2.4
Belgium	2.2
Chile	1.3
Finland	0.7
United States	0.3
Other assets (liabilities)	(0.4)

SECTOR ALLOCATION	% OF NAV
Health care	20.0
Financials	12.3
Consumer discretionary	10.6
Industrials	10.4
Consumer staples	10.1
Materials	9.0
Energy	8.4
Information technology	7.8
Cash and cash equivalents	5.3
Utilities	5.0
Communication services	1.5
Other assets (liabilities)	(0.4)

TOP 25 POSITIONS	% OF NAV
Issuer	
Novo Nordisk AS	6.1
Cash and cash equivalents	5.3
Shell PLC	4.6
AstraZeneca PLC	4.4
ASML Holding NV	4.0
Novartis AG	3.8
Total SA	3.1
Nestle SA	2.6
AXA SA	2.3
ING Groep NV	2.2
UCB SA	2.2
Industria de Diseno Textil SA (Inditex)	2.0
Enel SpA	1.9
Iberdrola SA	1.8
Compass Group PLC	1.7
Roche Holding AG	1.7
Heineken NV	1.6
Unilever PLC	1.6
Muenchener Rueckversicherungs – Gesellschaft AG	1.6
Prudential PLC	1.6
Bank of Ireland Group PLC	1.5
DCC PLC	1.5
Sandvik AB	1.5
CRH PLC	1.4
Pandora AS	1.4
Top long positions as a percentage	
of total net asset value	63.4
Total net asset value of the Fund	\$2.4 billion

The Fund held no short positions at the end of the period.

The investments and percentages may have changed since June 30, 2024, due to the ongoing portfolio transactions of the Fund. Quarterly updates of holdings are available within 60 days of the end of each quarter except for March 31, the Fund's fiscal year-end, when they are available within 90 days.

